Boston Scientific Reports Q3 2026 Sales of $5.14 Billion, Adjusted EPS of $0.73
Boston Scientific reported Q3 2026 net sales of $5.14B, up 1.5% YoY, and adjusted EPS of $0.73. The company lowered its full-year 2026 outlook to 4.25% sales growth and adjusted EPS of $3.16-$3.18. Gross profit and operating income declined YoY. The company announced new product clearances and collaborations.
How this was made
The 30-second read
Why it matters
The revised guidance is likely to drive the stock lower as investors adjust expectations for 2026 performance.
Market read
The earnings release and guidance cut are the primary drivers of short‑term market reaction for BSX and may influence the broader med‑tech sector.
What to watch
Upcoming FDA clearances for new StoneSmart technologies and the Heartflow collaboration could offset short‑term guidance weakness.
Background
Boston Scientific reported modest Q3 sales growth and a decline in operating income, prompting a reduction in its full‑year outlook.
Ticker impact
Boston Scientific disclosed Q3 2026 results and cut full‑year sales growth outlook to ~4.25% and adjusted EPS guidance to $3.16‑$3.18, a fresh earnings release with revised guidance.
downward pressure as investors price in lower sales growth and EPS expectations
The company lowered its full‑year outlook after reporting modest Q3 growth, a material change that typically triggers a negative reaction in the stock.
Market effects
Medical device sector may see broader pressure as peers' guidance cuts raise concerns about demand slowdown.
U.S. healthcare stocks could face short‑term weakness in the afternoon session.
Limited; impact confined mainly to U.S. listed med‑tech equities.
Counterpoint
If the guidance cut reflects a temporary slowdown and the company’s pipeline remains strong, the dip could present a buying opportunity.
Key entities
- CompanyBoston Scientific
Medical device manufacturer reporting Q3 2026 results and lowering full‑year guidance.
